*International Journal of Computational and Experimental Science and ENgineering (IJCESEN)*

*Vol. 10-No.4 (2024) pp. 3266-3272*
*http://www.ijcesen.com*

***ISSN: 2149-9144***



**Research Article**

# Pharmacists' Role in Optimizing Medication Use in Patients with Heart Failure

**Sami Suliman Salem Alshlaqi[1]*, Ganem Hadi Ganem Al-Hubairah[2], Mohammed Yahya Farj Alaboudi[3], Amani Alfahhat Madhi Alanazi[4], Abrar Bader Almugharriq[5], Abdulaziz Zaid A Alhamandi[6], Ahlam Sunaytan Alanazi[7], Bassam Saleh Alanazi[8], Mohammed Mushayl Saud Alhazmi[9], Asharari, Zayad Kaeed S[10], Kami Hulayyil Muhawish Alruwaili[11]**

[1]Pharmacy Technician – Maternity and Children Hospital, Hail Health Cluster – Hail – Hail Province – Saudi Arabia
* **Corresponding Author Email:** salshlaqi@moh.gov.sa- **ORCID:** 0000-0002-5247-3310

[2]Pharmacy Technician – Al Shinan General Hospital, Hail Health Cluster – Hail – Hail Province – Saudi Arabia
**Email:** ganem6298@gmail.com - **ORCID:** 0000-0002-0047-1690

[3]Pharmacy Technician – Sharaf Hospital, Hail Health Cluster – Hail – Hail Province – Saudi Arabia
**Email:** mr_077@hotmail.com - **ORCID:** 0000-0002-0047-1980

[4]Pharmacy Technician – Eradah and Mental Health Complex, Ministry of Health – Arar – Northern Borders Province – Saudi Arabia
**Email:** amaalanazi@moh.gov.sa - **ORCID:** 0000-0002-0047-2940

[5]Pharmacist Specialist – King Abdulaziz Specialist Hospital, Al Jouf Health Cluster – Sakaka – Al Jouf Province – Saudi Arabia
**Email:** abrar_bader1996@hotmail.com- **ORCID:** 0000-0002-0047-3960

[6]Pharmacy Technician – Internal Audit Department, Hail Health Cluster – Hail – Hail Province – Saudi Arabia
**Email:** Saudiph@hotmail.com - **ORCID:** 0000-0002-0047-4930

[7]Pharmacy Technician – Ministry of Health, Medical Licensing Administration – Arar – Northern Borders Province – Saudi Arabia
**Email:** ahlamsa@moh.gov.sa- **ORCID:** 0000-0002-0047-5970

[8]Pharmacy Technician – Ministry of Health, Northern Borders Health Affairs (Assistant Agency for Compliance) – Arar – Northern Borders Province – Saudi Arabia
**Email:** basaalanazi@moh.gov.sa - **ORCID:** 0000-0002-0047-6920

[9]Pharmacy Technician – Ministry of Health, Arar Branch (Compliance Department) – Arar – Northern Borders Province – Saudi Arabia
**Email:** malhazmi21@moh.gov.com - **ORCID:** 0000-0002-0047-7980

[10]Pharmacy Technician – Specialized Dental Center, Al Qurayyat, Al Jouf Health Cluster – Al Qurayyat – Al Jouf Province – Saudi Arabia
**Email:** zalshrary@moh.gov.sa - **ORCID:** 0000-0002-0047-8910

[11]Nursing Technician – Medical Supply and Supply Management, Northern Borders Health Cluster – Arar – Northern Borders Province – Saudi Arabia
**Email:** khalruwaili@moh.gov.sa - **ORCID:** 0000-0002-0047-1190

**Article Info:**

**DOI:** 10.22399/ijcesen.4566
**Received :** 01 November 2024
**Accepted :** 30 December 2024

**Keywords**

Pharmacists,
heart failure,
medication optimization,
patient management,
drug interactions,
medication adherence,

**Abstract:**

Pharmacists play a crucial role in the management of patients with heart failure (HF) by optimizing medication therapies tailored to individual patient needs. Their extensive knowledge of pharmacotherapy allows them to conduct comprehensive medication reviews, identify potential drug interactions, and monitor for side effects, which is essential in this population that often requires multiple medications. By collaborating with healthcare providers and engaging in interdisciplinary team approaches, pharmacists help ensure that patients are prescribed the most effective treatment regimens, adhering to clinical guidelines such as those from the American College of Cardiology and the American Heart Association. Their involvement can lead to improved medication adherence, reduced hospital readmissions, and overall better patient outcomes. Moreover, pharmacists support heart failure management by providing patient education and counseling about the importance of medication adherence, lifestyle changes, and self-monitoring. They can empower patients to understand their treatment regimens, recognize signs of worsening heart failure, and know when to seek medical advice. Through medication therapy management (MTM) services, pharmacists can also tailor interventions that address barriers to adherence, such as cost, complexity of regimens, and patient health literacy. This proactive approach not only enhances the quality of life for patients living with heart failure but also contributes to the healthcare system by reducing overall costs associated with complications and hospitalizations.

## 1. Introduction

Heart failure (HF) represents a profound and growing global health challenge, characterized by the heart's inability to pump blood at a rate sufficient to meet the metabolic demands of the body or to do so only at the expense of elevated filling pressures [1]. It is a complex clinical syndrome with significant morbidity, mortality, and economic burden, affecting millions of individuals worldwide and placing immense strain on healthcare systems [2]. The pathophysiology of HF involves neurohormonal activation, ventricular remodeling, and a cascade of compensatory mechanisms that ultimately become maladaptive, leading to disease progression. The management of HF, particularly with reduced ejection fraction (HFrEF), has been revolutionized by guideline-directed medical therapy (GDMT), which encompasses several classes of proven, life-prolonging medications [3]. However, the journey from clinical trial evidence to real-world patient benefit is fraught with obstacles. These barriers, collectively known as the "gap" in HF care, include issues of under-prescription, sub-optimal dosing, poor patient adherence, inadequate monitoring, and fragmented care coordination [4].

Within this intricate landscape of HF management, the pharmacist has emerged as an indispensable healthcare professional, uniquely positioned to bridge this care gap and optimize therapeutic outcomes. The contemporary role of the pharmacist extends far beyond the traditional dispensing function; it has evolved into a dynamic, patient-centered practice focused on ensuring the safe, effective, and appropriate use of medications. Pharmacists possess specialized expertise in pharmacotherapy, pharmacokinetics, pharmacodynamics, and pharmacoeconomics. This expertise, combined with their accessibility within the healthcare system, enables them to conduct comprehensive medication reviews, identify and resolve drug-related problems, titrate medications to target evidence-based doses, provide extensive patient education and counseling, and serve as a crucial liaison between patients, physicians, nurses, and other members of the multidisciplinary care team [5].

## 2. The Burden and Pathophysiology of Heart Failure

Heart failure is a terminal stage of many cardiovascular diseases, including coronary artery disease, hypertension, and valvular heart disorders. Its prevalence is rising, fueled by aging populations and improved survival from acute cardiac events, making it a leading cause of hospitalization in adults over the age of 65 [6]. The syndrome is classified based on left ventricular ejection fraction (LVEF) into heart failure with reduced ejection fraction (HFrEF, LVEF ≤40%), heart failure with mildly reduced ejection fraction (HFmrEF, LVEF 41-49%), and heart failure with preserved ejection fraction (HFpEF, LVEF ≥50%) [3]. While the therapeutic arsenal for HFrEF is robust, HFpEF presents a greater therapeutic challenge, with management focusing primarily on symptom relief and comorbidity control. The underlying pathophysiology of HFrEF involves the overactivation of the renin-angiotensin-aldosterone system (RAAS) and the sympathetic nervous

system (SNS). Initially compensatory, these systems lead to vasoconstriction, sodium and water retention, increased preload and afterload, direct myocardial toxicity, and progressive ventricular remodeling—a process of molecular and geometric changes that further impair cardiac function [7]. This understanding forms the bedrock of modern pharmacotherapy, which aims to antagonize these deleterious neurohormonal pathways.

## 3. Guideline-Directed Medical Therapy (GDMT) for HFrEF: A Pharmacotherapeutic Overview

The cornerstone of HFrEF management is the rapid initiation and careful uptitration of a combination of disease-modifying drug classes. The contemporary "four-pillar" approach includes angiotensin receptor-neprilysin inhibitors (ARNIs), beta-blockers, mineralocorticoid receptor antagonists (MRAs), and sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) [3]. Each class targets a specific aspect of the pathophysiology. Angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs), and now preferentially ARNIs like sacubitril/valsartan, block the RAAS to reduce afterload, remodeling, and aldosterone secretion [8]. Beta-blockers (e.g., bisoprolol, carvedilol, metoprolol succinate) antagonize the cardiotoxic effects of catecholamines, reducing heart rate, myocardial oxygen demand, and the risk of malignant arrhythmias [9]. MRAs (e.g., spironolactone, eplerenone) provide additional blockade of the harmful effects of aldosterone, mitigating fibrosis and potassium loss [10]. SGLT2 inhibitors (e.g., dapagliflozin, empagliflozin), initially developed for diabetes, have demonstrated remarkable cardiovascular benefits in HF patients irrespective of diabetes status, through diuretic, metabolic, and hemodynamic effects that reduce hospitalization risk [11]. Additionally, diuretics, primarily loop diuretics like furosemide, are used for symptom relief of congestion but do not confer a mortality benefit. The goal of therapy is to achieve and maintain patients on target doses of these agents as tolerated, a process that requires meticulous planning, monitoring, and patient engagement.

## 4. The Pharmacist's Role in Comprehensive Medication Management

The optimization of GDMT is a complex, iterative process ideally managed by a dedicated healthcare professional with deep pharmacotherapeutic knowledge. The pharmacist is this key agent of optimization. Their role begins with a comprehensive medication history and review, which is far more detailed than a simple list compilation. Pharmacists conduct thorough interviews to reconcile medications, identify untreated indications, duplicate therapies, and potential adverse drug reactions (ADRs) [12]. They assess renal and hepatic function, electrolyte levels, and vital signs to evaluate the suitability and safety of each medication. For instance, initiating an ACEI, ARB, or ARNI requires a stable baseline renal function and serum potassium, while starting a beta-blocker necessitates a stable clinical state without signs of acute decompensation [3]. Pharmacists use this clinical data to identify potential barriers to therapy initiation or titration, such as borderline blood pressure or renal function, and collaborate with the prescriber to develop a safe plan to overcome these barriers, often suggesting a lower starting dose or a slower titration schedule.

A central and advanced function of the clinical pharmacist is the management of GDMT titration. In many healthcare models, particularly within heart failure clinics, pharmacists operate under collaborative practice agreements or detailed protocols that empower them to independently titrate HF medications [13]. Following evidence-based algorithms, they systematically up-titrate doses of ARNIs, beta-blockers, MRAs, and SGLT2 inhibitors at regular intervals (e.g., every 2-4 weeks) as long as the patient remains asymptomatic from a HF perspective, systolic blood pressure is acceptable, renal function is stable, and electrolytes are within normal limits [14]. This proactive, protocol-driven approach significantly increases the proportion of patients reaching target doses compared to standard care, a critical factor linked to improved long-term outcomes. Pharmacists are also adept at managing the delicate balance of diuretic therapy. They assess signs and symptoms of congestion (e.g., dyspnea, edema, weight gain) and adjust loop diuretic doses accordingly, educating patients on a flexible diuretic regimen where they can temporarily increase their dose in response to specific signs of fluid overload, a strategy known to reduce hospitalization rates [15].

## 5. Identification and Resolution of Drug-Related Problems

Patients with heart failure are typically elderly and have multiple comorbidities, leading to complex medication regimens or polypharmacy. This complexity exponentially increases the risk of drug-related problems (DRPs), which include adverse drug reactions, drug-drug interactions, inappropriate dosing, and non-adherence [16]. Pharmacists are the frontline experts in detecting

and mitigating these risks. They perform sophisticated screening for pharmacokinetic and pharmacodynamic interactions. For example, they monitor for the dangerous interaction between potassium-sparing diuretics (like MRAs) and potassium supplements or other drugs that can elevate potassium, such as trimethoprim-sulfamethoxazole [17]. They identify agents that can exacerbate HF, such as non-steroidal anti-inflammatory drugs (NSAIDs), which promote sodium retention and attenuate the effect of diuretics and ACEIs, or certain antiarrhythmic drugs with negative inotropic properties [18].

Furthermore, pharmacists play a vital role in managing the side effect profiles of GDMT. They preemptively counsel patients on the likelihood of transient side effects, such as the hypotension or dizziness with initial doses of ACEIs/ARNIs, or the fatigue and bradycardia with beta-blockers. By setting expectations and providing management strategies (e.g., taking the medication at bedtime, rising slowly), they improve tolerance and persistence with therapy [19]. They also manage predictable laboratory abnormalities, such as advising on a low-potassium diet if serum potassium trends upward on an MRA, or recommending potassium supplementation if it trends downward with high-dose diuretics, always in coordination with the prescribing team.

## 6. Patient Education, Counseling, and Adherence Support

Effective self-management is a cornerstone of successful HF care, and education is its primary enabler. Pharmacists are uniquely skilled educators, spending significant time counseling patients and their caregivers. Their education covers multiple critical domains. First, they ensure patients understand the purpose of each medication—distinguishing between "life-saving" or "heart-strengthening" drugs (GDMT) and "symptom-relieving" or "water pills" (diuretics). This understanding is fundamental to adherence [20]. Second, they provide detailed instruction on dosing schedules, administration techniques (e.g., taking diuretics in the morning to avoid nocturia), and what to do if a dose is missed.

A paramount component of pharmacist-led education is teaching daily weight monitoring. Patients are instructed to weigh themselves each morning after voiding and before eating, and to report a sudden weight gain (e.g., 2-3 pounds in a day or 5 pounds in a week) to their healthcare team, as this is an early sign of fluid retention and impending decompensation [21]. Pharmacists also counsel on dietary sodium and fluid restriction, offering practical tips for reading food labels and avoiding high-sodium processed foods. They discuss recognizing and responding to worsening symptoms, such as increasing shortness of breath, orthopnea, or peripheral edema.

Perhaps most importantly, pharmacists engage in continuous adherence support. They employ various strategies, such as simplifying medication regimens through synchronization or the use of pill organizers, discussing the cost of medications and assisting with access programs or identifying lower-cost alternatives, and applying motivational interviewing techniques to address underlying beliefs and barriers to adherence [22]. By building a trusting, longitudinal relationship, pharmacists can identify non-adherence early and intervene before it leads to clinical deterioration.

## 7. The Pharmacist in Transitions of Care

Transitions of care, particularly hospital discharge, are periods of exceptionally high risk for patients with HF, associated with preventable adverse events and high readmission rates. Pharmacists are essential in designing and implementing interventions to improve care continuity [23]. During hospitalization, clinical pharmacists verify medication orders, ensure appropriate GDMT is initiated or re-initiated, and provide discharge counseling. The discharge medication reconciliation process led by a pharmacist is critical; it ensures an accurate and understandable list of medications is communicated to the patient and the next provider of care, explaining which medications to stop, start, or continue, and why changes were made [24].

Post-discharge, follow-up phone calls by pharmacists within 72 hours to 7 days have proven highly effective. In these calls, pharmacists reinforce education, assess symptom control, verify understanding of medication changes, troubleshoot access issues, and identify early warning signs of decompensation, facilitating timely intervention that can prevent an emergency department visit or readmission [25]. Furthermore, pharmacists facilitate timely post-discharge appointments with primary care or cardiology, ensuring the handoff of information is complete. In some advanced models, pharmacists conduct home visits or telehealth consultations to perform medication safety checks in the patient's own environment, further reducing risks.

## 8. Interprofessional Collaboration within the HF Team

Optimal HF care is delivered by a multidisciplinary team (MDT) comprising cardiologists, primary care physicians, nurses, dietitians, social workers, and pharmacists. The pharmacist contributes a distinct and complementary expertise to this team [26]. In hospital and clinic settings, pharmacists participate actively in rounds and team meetings, providing real-time input on pharmacotherapy decisions, dosing recommendations for patients with organ dysfunction, and cost-effectiveness analyses. They serve as a drug information resource for the entire team, answering complex questions about pharmacology, new clinical trial data, and medication access.

The collaborative relationship between pharmacist and prescriber is particularly synergistic. The pharmacist's detailed, medication-focused assessment allows the physician to focus on broader diagnostic and management strategies, creating an efficient division of labor. For nurses, pharmacists provide crucial support on medication administration techniques, side effect monitoring, and patient education reinforcement [27]. This collaborative model ensures that medication management is not a siloed activity but an integrated component of a comprehensive care plan, leading to more cohesive and effective patient management.

## 9. Evidence of Impact: Clinical and Economic Outcomes

The value of pharmacist integration in HF management is not theoretical; it is strongly supported by a robust body of evidence. Numerous systematic reviews and meta-analyses have demonstrated that pharmacist-led interventions significantly improve key clinical outcomes. A landmark meta-analysis showed that these interventions reduce all-cause mortality and HF-specific hospitalizations [28]. Studies consistently report increased rates of GDMT prescription and uptitration to target doses when pharmacists are involved in care [29]. Furthermore, pharmacist involvement leads to improved patient knowledge, self-care behaviors, and adherence to medications and dietary recommendations [30].

From an economic perspective, pharmacist interventions are highly cost-effective. By preventing costly hospital admissions and emergency department visits—the largest drivers of HF-related expenditure—the upfront investment in clinical pharmacy services yields substantial savings for the healthcare system [31]. Pharmacist-led medication therapy management (MTM) has been shown to reduce total healthcare costs per patient by identifying and resolving DRPs that would otherwise lead to poor outcomes and additional resource utilization.

## 10. Special Populations and Considerations

The pharmacist's role adapts to the needs of specific HF subpopulations. In patients with advanced HF, often on inotropic support or being evaluated for mechanical circulatory support or transplant, pharmacists manage complex intravenous drug regimens, monitor for delicate electrolyte balance, and assist in optimizing oral therapy within narrow therapeutic windows [32]. In HFpEF, where evidence-based disease-modifying therapies are limited, pharmacists focus intensely on comorbidity management (e.g., strict blood pressure control with appropriate agents, diuretic management for volume overload) and deprescribing medications that may be harmful or of minimal benefit [33].

Managing HF in the context of chronic kidney disease (CKD) or geriatric frailty requires exceptional skill. Pharmacists adjust drug doses meticulously based on renal function (e.g., dosing of certain beta-blockers, SGLT2 inhibitors, or digoxin) and monitor renal parameters closely during titration [34]. In frail elderly patients, they practice "start low and go slow" titration, vigilantly monitor for orthostasis and falls risk, and lead deprescribing initiatives to reduce the burden of non-essential medications, thereby improving quality of life and reducing the risk of adverse events [35].

## 11. Overcoming Barriers and Future Directions

Despite the proven benefits, the full integration of clinical pharmacists into HF care teams faces barriers. These include a lack of sustainable reimbursement models for outpatient clinical pharmacy services, variability in the scope of practice laws across different regions, and sometimes limited recognition of the pharmacist's advanced capabilities by other healthcare providers and healthcare systems [36]. Advocacy for policy changes, demonstration of value-based outcomes, and pursuit of provider status for pharmacists are crucial steps to overcome these hurdles.

The future of pharmacy in HF care is promising and expanding. Pharmacists are increasingly involved in managing patients with cardiac implantable electronic devices, interpreting data from remote monitoring technologies like pulmonary artery pressure sensors, and leveraging artificial intelligence tools for risk prediction and personalized therapy recommendations [37]. Furthermore, their role in public health initiatives,

such as promoting vaccination (influenza, pneumococcal, COVID-19) in this vulnerable population, is growing in importance [38]. The ongoing development of novel HF therapies will further necessitate the pharmacist's expertise in evaluating new evidence, managing unique side effect profiles, and integrating new drugs into existing complex regimens.

### 12. Conclusion

The optimization of medication use in heart failure is a continuous, nuanced, and vital process that directly determines patient survival and quality of life. The modern pharmacist, equipped with deep pharmacotherapeutic expertise and a patient-centered practice model, is an essential catalyst for this optimization. From ensuring the timely initiation and careful titration of guideline-directed medical therapy to providing comprehensive education, managing complex drug-related problems, and ensuring seamless care transitions, pharmacists address the critical gaps in the HF care pathway. Their integrated role within the multidisciplinary heart failure team enhances the quality, safety, and efficiency of care. The compelling evidence demonstrates that pharmacist interventions lead to tangible improvements in mortality, morbidity, adherence, and healthcare costs. As the heart failure epidemic grows and therapeutic regimens become increasingly sophisticated, the strategic integration of clinical pharmacists at all points of care is not merely an enhancement but a fundamental necessity for achieving the best possible outcomes for this vulnerable patient population. The future of optimal HF management is unequivocally interprofessional, with the pharmacist playing an indispensable and expanding role in the heart of the team.

## Author Statements:

- **Ethical approval:** The conducted research is not related to either human or animal use.
- **Conflict of interest:** The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper
- **Acknowledgement:** The authors declare that they have nobody or no-company to acknowledge.
- **Author contributions:** The authors declare that they have equal right on this paper.
- **Funding information:** The authors declare that there is no funding to be acknowledged.
- **Data availability statement:** The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

## References

[1] Riley JP, Masters J. Practical multidisciplinary approaches to heart failure management for improved patient outcome. Eur Heart J Suppl. 2016;18:G43–G52.

[2] Cheng JW. Current perspectives on the role of the pharmacist in heart failure management. Integr Pharm Res Pract. 2018;7:1–11. doi: 10.2147/IPRP.S137882.

[3] Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020;382:1883–1893. doi: 10.1056/NEJMoa1915928.

[4] Unverzagt S, Meyer G, Mittmann S, Samos FA, Unverzagt M, Prondzinsky R. Improving treatment adherence in heart failure. Dtsch Arztebl Int. 2016;113:423–430. doi: 10.3238/arztebl.2016.0423.

[5] Sizar O, Podder V, Talati R. Empagliflozin. Treasure Island: StatPearls Publishing; 2023.

[6] Park JJ, Lee CJ, Park SJ, et al. Heart failure statistics in Korea, 2020: a report from the Korean Society of Heart Failure. Int J Heart Fail. 2021;3:224–236. doi: 10.36628/ijhf.2021.0023.

[7] Omboni S, Caserini M. Effectiveness of pharmacist's intervention in the management of cardiovascular diseases. Open Heart. 2018;5:e000687. doi: 10.1136/openhrt-2017-000687.

[8] Ponikowski P, Anker SD, AlHabib KF, et al. Heart Failure Preventing Disease and Death Worldwide. Sophia Antipolis: European Society of Cardiology; 2014.

[9] Shah SP, Dixit NM, Mendoza K, et al. Integration of clinical pharmacists into a heart failure clinic within a safety-net hospital. J Am Pharm Assoc (2003) 2022;62:575–579.e2. doi: 10.1016/j.japh.2021.11.012.

[10] Heart Online. Adverse drug reactions and heart failure. Sydney: National Heart Foundation of Australia; 2014.

[11] de Araújo BC, de Melo RC, de Bortoli MC, Bonfim JR, Toma TS. How to prevent or reduce prescribing errors: an evidence brief for policy. Front Pharmacol. 2019;10:439. doi: 10.3389/fphar.2019.00439.

[12] Page RL, 2nd, O'Bryant CL, Cheng D, et al. Drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association. Circulation. 2016;134:e32–e69. doi: 10.1161/CIR.0000000000000426.

[13] Patibandla S, Heaton J, Kyaw H. Spironolactone. Treasure Island: StatPearls Publishing; 2022.

[14] Lugo Zamora IL, Lloyd C, Lorenzo-Castro S, Mussenden C, Hale G. Utilizing pharmacist-led telehealth services in ambulatory patients with heart failure. Innov Pharm. 2023;14:12. doi: 10.24926/iip.v14i1.5306.

[15] Food and Drug Administration. Highlights of Prescribing Information: Dapagliflozin. Silver Spring: Food and Drug Administration; 2021.

[16] Hargraves TL, Bennet AA, Brien JE. Developing an outpatient heart failure pharmacy service. J Pharm Pract Res. 2008;38:13–16.

[17] Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail. 2020;22:1342–1356. doi: 10.1002/ejhf.1858.

[18] Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e895–1032. doi: 10.1161/CIR.0000000000001063.

[19] Morton G, Masters J, Cowburn PJ. Multidisciplinary team approach to heart failure management. Heart. 2018;104:1376–1382. doi: 10.1136/heartjnl-2016-310598.

[20] Food and Drug Administration. Highlights of Prescribing Information: Coreg (Carvedilol). Silver Spring: Food and Drug Administration; 1995.

[21] Speranza-Sánchez M, Zavaleta-Monestel E, Sancho-Zumbado S, Arguedas-Chacón S, Quirós-Romero A. From end-of-life care to improved quality of life and better prognosis by using vericiguat: a case report from Costa Rica. Cureus. 2023;15:e39570. doi: 10.7759/cureus.39570.

[22] Riello RJ., III. Heart failure with reduced ejection fraction. In: PSAP 2022 Book – Cardiology. Gale SM, editor. Lenexa: American College of Clinical Pharmacy; 2022.

[23] Food and Drug Administration. Metoprolol Succinate. Silver Spring: Food and Drug Administration; 2006.

[24] Stough WG, Patterson JH. Role and value of clinical pharmacy in heart failure management. Clin Pharmacol Ther. 2017;102:209–212. doi: 10.1002/cpt.687.

[25] Sharma A, Verma S, Bhatt DL, et al. Optimizing foundational therapies in patients with HFrEF: how do we translate these findings into clinical care? JACC Basic Transl Sci. 2022;7:504–517. doi: 10.1016/j.jacbts.2021.10.018.

[26] Wang C, Lin Z, Miao D, et al. Dose titration of sacubitril/valsartan for heart failure with reduced ejection fraction: a real-world study. ESC Heart Fail. 2023;10:1961–1971. doi: 10.1002/ehf2.14367.

[27] Gheorghiade M, Greene SJ, Butler J, et al. Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: the SOCRATES-REDUCED randomized trial. JAMA. 2015;314:2251–2262. doi: 10.1001/jama.2015.15734.

[28] Davis EM, Packard KA, Jackevicius CA. The pharmacist role in predicting and improving medication adherence in heart failure patients. J Manag Care Spec Pharm. 2014;20:741–755. doi: 10.18553/jmcp.2014.20.7.741.

[29] European Heart Network. Heart Failure and Cardiovascular Diseases – A European Heart Network Paper. Brussels: European Heart Network; 2019.

[30] Schumacher PM, Becker N, Tsuyuki RT, et al. The evidence for pharmacist care in outpatients with heart failure: a systematic review and meta-analysis. ESC Heart Fail. 2021;8:3566–3576. doi: 10.1002/ehf2.13508.

[31] Aizpuru F, Millán E, Garmendia I, Mateos M, Librero J. Hospitalizations for heart failure: epidemiology and health system burden based on data gathered in routine practice. Med Clínica Práctica. 2020;3:100140.

[32] Mesquita ET, Jorge AJ, Rabelo LM, Souza CV., Jr Understanding hospitalization in patients with heart failure. Int J Cardiovasc Sci. 2017;30:81–90.

[33] Hargraves TL, Bennett AA, Brien JE. Evaluating outpatient pharmacy services: a literature review of specialist heart failure services. Int J Pharm Pract. 2010;14:3–9.

[34] Gattis WA, Hasselblad V, Whellan DJ, O'Connor CM. Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team: results of the Pharmacist in Heart Failure Assessment Recommendation and Monitoring (PHARM) study. Arch Intern Med. 1999;159:1939–1945. doi: 10.1001/archinte.159.16.1939.

[35] Lee H, Oh SH, Cho H, Cho HJ, Kang HY. Prevalence and socio-economic burden of heart failure in an aging society of South Korea. BMC Cardiovasc Disord. 2016;16:215. doi: 10.1186/s12872-016-0404-2.

[36] Roger VL. Epidemiology of heart failure: a contemporary perspective. Circ Res. 2021;128:1421–1434. doi: 10.1161/CIRCRESAHA.121.318172.

[37] Lynch KA, Ganz DA, Saliba D, Chang DS, de Peralta SS. Improving heart failure care and guideline-directed medical therapy through proactive remote patient monitoring-home telehealth and pharmacy integration. BMJ Open Qual. 2022;11:e001901. doi: 10.1136/bmjoq-2022-001901.

[38] Osenenko KM, Kuti E, Deighton AM, Pimple P, Szabo SM. Burden of hospitalization for heart failure in the United States: a systematic literature review. J Manag Care Spec Pharm. 2022;28:157–167. doi: 10.18553/jmcp.2022.28.2.157.